In 2018 Mill identified a new therapeutic technique for primary ciliary dyskinesia (PCD).[11] She proposed that drugs which make dynein motor proteins functional could improve the quality of life of patients suffering from primary ciliary dyskinesia.[11][12] In October 2018 Mill chaired the first PCD awareness day.[13] She proposed that the Government of the United Kingdom introduced early genetic diagnosis of PCD for babies with no identified causes of neonatal respiratory distress.[14] She hopes that genome editing will be able to treat PCD.